Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.

Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure

Open access

Abstract

BACKGROUND: Despite intense research, it remains intriguing why hormonal therapies in general and progestins in particular sometimes fail in endometriosis. OBJECTIVE AND RATIONALE: We review here the action mechanisms of progesterone receptor ligands in endometriosis, identify critical differences between the effects of progestins on normal endometrium and endometriosis and envisage pathways to escape drug resistance and improve the therapeutic response of endometriotic lesions to such treatments. SEARCH METHODS: We performed a systematic Pubmed search covering articles published since 1958 about the use of progestins, estro-progestins and selective progesterone receptor modulators, to treat endometriosis and its related symptoms. Two reviewers screened the titles and abstracts to select articles for full-text assessment. OUTCOMES: Progesterone receptor signalling leads to down-regulation of estrogen receptors and restrains local estradiol production through interference with aromatase and 17 beta-hydroxysteroid dehydrogenase type 1. Progestins inhibit cell proliferation, inflammation, neovascularisation and neurogenesis in endometriosis. However, progesterone receptor expression is reduced and disrupted in endometriotic lesions, with predominance of the less active isoform (PRA) over the full-length, active isoform (PRB), due to epigenetic abnormalities affecting the PGR gene transcription. Oxidative stress is another mechanism involved in progesterone resistance in endometriosis. Among the molecular targets of progesterone in the normal endometrium that resist progestin action in endometriotic cells are the nuclear transcription factor FOXO1, matrix metalloproteinases, the transmembrane gap junction protein connexin 43 and paracrine regulators of estradiol metabolism. Compared to other phenotypes, deep endometriosis appears to be more resistant to size regression upon medical treatments. Individual genetic characteristics can affect the bioavailability and pharmacodynamics of hormonal drugs used to treat endometriosis and, hence, explain part of the variability in the therapeutic response. WIDER IMPLICATIONS: Medical treatment of endometriosis needs urgent innovation, which should start by deeper understanding of the disease core features and diverse phenotypes and idiosyncrasies, while moving from pure hormonal treatments to drug combinations or novel molecules capable of restoring the various homeostatic mechanisms disrupted by endometriotic lesions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humupd/dmaa009

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of nuclear progesterone receptors A (PRA) and B (PRB) and membrane receptors PGRMC-1 and PGRMC-2 during the menstrual cycle in human endometrium. The dot density indicates the abundance of the represented molecule at each cycle phase and tissue compartment (glands or stroma), according to immunolocalisation (Bedaiwy et al., 2015; Keator et al., 2012; Mote et al., 1999), western blotting (Bedaiwy et al., 2015), real-time PCR and in situ hybridisation (Keator et al., 2012). Note, the maximal expression of PRA and PRB in the late proliferative phase (dotted rectangle) and the transient increase in stromal PRA expression at mid-secretory phase (dotted circle).
Figure 1 Schematic representation of nuclear progesterone receptors A (PRA) and B (PRB) and membrane receptors PGRMC-1 and PGRMC-2 during the menstrual cycle in human endometrium. The dot density indicates the abundance of the represented molecule at each cycle phase and tissue compartment (glands or stroma), according to immunolocalisation (Bedaiwy et al., 2015; Keator et al., 2012; Mote et al., 1999), western blotting (Bedaiwy et al., 2015), real-time PCR and in situ hybridisation (Keator et al., 2012). Note, the maximal expression of PRA and PRB in the late proliferative phase (dotted rectangle) and the transient increase in stromal PRA expression at mid-secretory phase (dotted circle).CC BY-NC · PubMed Central
Figure 2 Therapeutic mechanisms of hormonal treatments for endometriosis. Progestins, selective progesterone receptor modulators (SPRMs) and combined contraceptives block ovulation through central inhibition of gonadotropin release, induce amenorrhea which prevents repeated menstrual reflux and have many direct effects on endometriotic implants. Gonadotropin-releasing hormone (GnRH) agonists and antagonists block ovulation and induce hypoestrogenism, while aromatase inhibitors such as letrozole reduce androgen aromatisation into estrogens, both in the adipose tissue and within endometriotic lesions.
Figure 2 Therapeutic mechanisms of hormonal treatments for endometriosis. Progestins, selective progesterone receptor modulators (SPRMs) and combined contraceptives block ovulation through central inhibition of gonadotropin release, induce amenorrhea which prevents repeated menstrual reflux and have many direct effects on endometriotic implants. Gonadotropin-releasing hormone (GnRH) agonists and antagonists block ovulation and induce hypoestrogenism, while aromatase inhibitors such as letrozole reduce androgen aromatisation into estrogens, both in the adipose tissue and within endometriotic lesions.CC BY-NC · PubMed Central
Figure 3 Effects of progestin treatment in vitro on normal endometrial cells compared to endometriotic cells cultured in parallel and under the same conditions. The arrows indicate that progestin treatment stimulates (↑), inhibits (↓) or has no effect (⇔) on the target gene, RNA or protein.
Figure 3 Effects of progestin treatment in vitro on normal endometrial cells compared to endometriotic cells cultured in parallel and under the same conditions. The arrows indicate that progestin treatment stimulates (↑), inhibits (↓) or has no effect (⇔) on the target gene, RNA or protein.CC BY-NC · PubMed Central
Figure 4 Endometriosis phenotype may affect the therapeutic response to progestins. The graphs summarise dysmenorrhea (A) and deep dyspareunia (B) scores obtained by visual analogue scale (VAS) in women with rectovaginal endometriosis (Ferrero et al., 2009) and in women with ovarian endometrioma (Ferrero et al., 2014) treated with norethisterone acetate for 6 months. Data were extracted from published tables of two separate studies and plotted together for better visualisation.
Figure 4 Endometriosis phenotype may affect the therapeutic response to progestins. The graphs summarise dysmenorrhea (A) and deep dyspareunia (B) scores obtained by visual analogue scale (VAS) in women with rectovaginal endometriosis (Ferrero et al., 2009) and in women with ovarian endometrioma (Ferrero et al., 2014) treated with norethisterone acetate for 6 months. Data were extracted from published tables of two separate studies and plotted together for better visualisation.CC BY-NC · PubMed Central
Figure 5 Hypothetical targets and strategies to overcome progesterone resistance in endometriosis based on currently available drugs. Progesterone receptor (PR) expression is inhibited by gene hypermethylation induced by proinflammatory cytokines and reactive oxygen species (ROS), which could be inhibited by anti-inflammatory drugs/immunomodulators and antioxidants, respectively. The same drugs and others, such as retinoids, may activate mechanisms downstream PR signalling that prevent endometriosis proliferation and fibrosis. Blue arrows: stimulation; red arrows: inhibition. ER: estrogen receptor; p-Akt: phosphorylated serine/threonine protein kinase B; p-ERK1/2: phosphorylated extracellular signal-regulated kinase 1/2; NF-κB: nuclear factor-kappa B; ADAM17: A disintegrin and metalloproteases metallopeptidase domain 17; TNF: tumour necrosis factor; IL: interleukin.
Figure 5 Hypothetical targets and strategies to overcome progesterone resistance in endometriosis based on currently available drugs. Progesterone receptor (PR) expression is inhibited by gene hypermethylation induced by proinflammatory cytokines and reactive oxygen species (ROS), which could be inhibited by anti-inflammatory drugs/immunomodulators and antioxidants, respectively. The same drugs and others, such as retinoids, may activate mechanisms downstream PR signalling that prevent endometriosis proliferation and fibrosis. Blue arrows: stimulation; red arrows: inhibition. ER: estrogen receptor; p-Akt: phosphorylated serine/threonine protein kinase B; p-ERK1/2: phosphorylated extracellular signal-regulated kinase 1/2; NF-κB: nuclear factor-kappa B; ADAM17: A disintegrin and metalloproteases metallopeptidase domain 17; TNF: tumour necrosis factor; IL: interleukin.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 210 references

Research works printed but not linked: 4

  1. Andrews, 1976, Hormone therapy of endometriosis - estrogen, androgens, progestin estrogens, Excerpta Med, 368, 46
  2. Gerdes, 1998, Cloning and tissue expression of two putative steroid membrane receptors, Biol Chem, 379, 907
  3. Iskhakova, 2006, Polymorphism of the arylamine-n-acetyltransferase gene in endometriosis patients in the Republic of Bashkortostan, Balk J Med Genet, 9, 55
  4. Rokitansky, 1860, Über Uterusdrüsen-Neubildungen in Uterus- und Ovarial-Sarcomen, Zeitschrift der Kaiserlich Koenigl Gesellschaft der Aerzte zu Wien, 37, 577

Cited by

See all 166

Metadata

Authors
Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F.
Affiliations
  • Universidade Federal de Minas Gerais (BR)
  • University of Siena (IT)
  • Inserm (FR)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author
Petraglia, Felice
Venue
Human Reproduction Update
Published
2020-05-16
Volume
26
Issue
4
Pages
565-585
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
OpenAlex
W3026807961
Cited by
166
References
210
Citations by year
2026: 30 · 2025: 23 · 2024: 29 · 2023: 26 · 2022: 27 · 2021: 30 · 2020: 1
FWCI
3.14
Type
journal article
Language
en
Open access
Locations
  • Human Reproduction Update (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
Funders
Conselho Nacional de Desenvolvimento Científico e Tecnológico (201876/2017-5)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
endometriosis, progesterone receptor, progestins, selective progesterone receptor modulators, drug resistance, progesterone receptor isoforms, epigenetic regulation, oxidative stress, FOXO1, matrix metalloproteinases, connexin 43, aromatase, estradiol metabolism, deep infiltrating endometriosis, endometriosis phenotypes, hormone therapy
MeSH terms
Endometriosis, Endometrium, Female, Fertility Agents, Female, Humans, Ligands, Peritoneal Diseases, Progestins, Progesterone, Receptors, Progesterone, Uterine Diseases, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. https://app.cochat.ai/papers/10.1093/humupd/dmaa009
The paper
Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F. (2020). Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Human Reproduction Update. https://doi.org/10.1093/humupd/dmaa009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.